Enabling On-Demand Therapies

Chris Hart, co-founder, president and CEO of Creyon Bio; discusses the proof-of-concept achieved with its recent N-of-1 therapy, the business model for Creyon, and the potential for its approach to reduce the time and cost of drug development.